Navigation Links
OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Date:2/4/2009

BOTHELL, WA, and VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the two-year survival rate from a Phase 1/2 clinical trial of OGX-011 in combination with first-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). At two years, 30% of patients who had received OGX-011 with first-line chemotherapy were alive. OncoGenex has previously reported a mature median survival of 14.1 months and a one-year survival rate of 54%.

For comparison, published studies using a platinum-based regimen plus gemcitabine as first-line chemotherapy for advanced NSCLC reported median survivals of 8 to 11 months and one-year survival rates of 33% to 43%. Market approval for Avastin plus paclitaxel and carboplatin chemotherapy for NSCLC was based on results showing a median survival of 12.3 months compared to 10.3 months for patients treated with chemotherapy alone. Survival rates for Avastin plus chemotherapy versus chemotherapy alone were reported as 51% versus 44% at one year and 23% versus 15% at two years, respectively.

"The two-year survival rate of 30% in our Phase 1/2 NSCLC study compares favorably to the survival reported for Avastin plus paclitaxel and carboplatin chemotherapy," said Scott Cormack, president and CEO of OncoGenex. "These data remain consistent with our Phase 2 data in prostate cancer suggesting that OGX-011 when added to chemotherapy may improve survival by blocking the production of clusterin, the protein associated with treatment resistance in various cancers."

    Non-Small Cell Lung Cancer Phase 1/2 Study Design with Updated Results as
    of January 23, 2009

This single-arm, open-label study enrolled 81 patients with Stage IIIB (18 percent) or Stage IV (82 percent) NSCLC who were treated with OGX-011 in combination w
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Rootstown, OH (PRWEB) January 22, 2015 Crystal ... announced today that it has received AOAC-PTM Certifications for the ... O111, O121, and O145; collectively referred to as STEC or ... at 1 colony forming unit (cfu) per 325 g of ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), a ... today that the Company closed its previously announced ... Jack W. Schuler , Birchview Fund LLC ... million, before offering expenses.  The proceeds will be ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) today reported the results ... 31, 2008. All dollar amounts referenced,herein are in Canadian ... our cash and cash equivalents totaled $9.8 million,compared with ... loss for the third quarter of 2008 was $2.6 ...
... in Composite Events When Using Routine ... FFR Guidance in Multi-Vessel Disease, WASHINGTON, ... the launch of the PrimeWire(TM) Pressure,Guidewire, and the s5-FFR Option ... in the U.S. The PrimeWire is Volcano,s newest pressure,guidewire, capable ...
... Pillar of Support for National Children,s Program, ... and Chief,Scientific Officer of Tishcon Corp and visionary ... of low income children in,America. In January 2000, ... Patel, and Vice President, Arun Chopra, initiated a,monthly ...
Cached Biology Technology:Vasogen Announces Third Quarter 2008 Results 2Vasogen Announces Third Quarter 2008 Results 3Vasogen Announces Third Quarter 2008 Results 4Vasogen Announces Third Quarter 2008 Results 5Vasogen Announces Third Quarter 2008 Results 6Vasogen Announces Third Quarter 2008 Results 7Vasogen Announces Third Quarter 2008 Results 8Vasogen Announces Third Quarter 2008 Results 9Vasogen Announces Third Quarter 2008 Results 10Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 2Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 3Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 4Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 5Tishcon Corp Reaches Donation Milestone Exceeds 1 Million Bottles of Multi-Vitamins for Nourish America 2Tishcon Corp Reaches Donation Milestone Exceeds 1 Million Bottles of Multi-Vitamins for Nourish America 3
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)... Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD and ... reports on the recent success of the Wocket™ smart wallet at CES ... smart wallet was named as one of the "11 Hot Products at ... Products Launched At CES So Far" by Newseveryday.com and "The top 10 ...
(Date:1/22/2015)...   EyeLock, Inc. , a market leader of iris-based identity ... to the new role of Senior Vice President of ... of mobile platforms and wearable solutions for EyeLock,s technologies. Gerber ... the semiconductor industry to his role at EyeLock, with expertise ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... great debate has raged over whether organic compounds and ... meteorite Allan Hills 84001 were processed by living creatures ... been under intense scrutiny ever since. Scientists at the ... fresh look at how material associated with carbonate globules ...
... concerns that hamper embryonic stem cell research, but they still ... with which adult stem cells differentiate into mature tissue the ... impossible for researchers to multiply them in the laboratory. And ... difficult to use them for treating disease. , Now, ...
... and Infectious Diseases (NIAID), part of the National Institutes ... anthrax toxin that worked well in small-scale animal tests. ... anthrax antitoxin is an important advance, not only for ... also because this technique could be used to design ...
Cached Biology News:Relic of life in that Martian meteorite? A fresh look 2Powerful technique for multiplying adult stem cells may aid therapies 2Powerful technique for multiplying adult stem cells may aid therapies 3Scientists design potent anthrax toxin inhibitor 2Scientists design potent anthrax toxin inhibitor 3
... PEP-152 is a 17 amino acid synthetic peptide whose sequence is ... (amino to carboxy terminus): C - N(217) - Q - ... - A - T - P - N - Y - ... may be used for neutralization and control experiments with the polyclonal ...
... a novel target for which no antibody exists? ... custom antibodies for a variety of pharmaceutical, biotech ... to put our technology and expertise in antibody ... to our patented RabMAb development technology , High ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
Biology Products: